-
Global Biotechnology & Pharmaceutical Markets7 days agoSecurity concerns in U.S., China reshaping biotech
BIOCENTURY | POLITICS, POLICY & LAWSECURITY CONCERNS IN U.S., CHINA RESHAPING BIOTECHPlus: Gilead’s $1.3B PepStar deal and Merck and Moderna’s melanoma vaccine
-
Regulatory Intelligence & Drug Approvals7 days agoWoodcock: New paradigm needed to unlock therapies for rare diseases
BIOCENTURY | GUEST COMMENTARYWOODCOCK: NEW PARADIGM NEEDED TO UNLOCK THERAPIES FOR RARE DISEASESFive reforms could make individualized therapies commercially viable — using authority FDA already has
-
Capital, M&A & Industry Strategy1 week agoAfter Lycia’s aftermarket surge, more biotechs look to NASDAQ: Finance Report
BIOCENTURY | FINANCEAFTER LYCIA’S AFTERMARKET SURGE, MORE BIOTECHS LOOK TO NASDAQ: FINANCE REPORTRezera, TriGemX, Prana aim to list via different methods; fundings for Disc, Arcus, Zai,...
-
Capital, M&A & Industry Strategy1 week agoLimited competition behind Icotyde may help justify Gilead’s $1.3B PepStar deal
BIOCENTURY | DEALSLIMITED COMPETITION BEHIND ICOTYDE MAY HELP JUSTIFY GILEAD’S $1.3B PEPSTAR DEALSan Francisco Bay Area biotech acquires oral IL-23R program from under-the-radar Chinese company, with...
-
Drug Discovery & Therapeutics1 week agoNow preclinical again, Star draws $200M from crossover syndicate
BIOCENTURY | FINANCENOW PRECLINICAL AGAIN, STAR DRAWS $200M FROM CROSSOVER SYNDICATE‘Series A-prime’ round follows 10-figure sale to Incyte of subsidiary that housed lead candidate for von...
-
Capital, M&A & Industry Strategy2 weeks agoDraft U.S. outbound investment rule could chill cross-border collaboration
BIOCENTURY | POLITICS, POLICY & LAWDRAFT U.S. OUTBOUND INVESTMENT RULE COULD CHILL CROSS-BORDER COLLABORATIONProposed COINS Act implementing rule allows licensing Chinese drugs, but seeks to limit...
-
Manufacturing, Supply Chain & Infrastructure2 weeks agoMerck and Moderna’s melanoma vaccine data bring adoption test into focus
BIOCENTURY | PRODUCT DEVELOPMENTMERCK AND MODERNA’S MELANOMA VACCINE DATA BRING ADOPTION TEST INTO FOCUSAdded benefit over adjuvant Keytruda must be weighed against personalized manufacturing demands and...
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoChina’s draft export controls lift a cloud — for now
BIOCENTURY | POLITICS, POLICY & LAWCHINA’S DRAFT EXPORT CONTROLS LIFT A CLOUD — FOR NOWProposal would bar platform technology sales while permitting most licensing and research...
-
Capital, M&A & Industry Strategy2 weeks agoAptaDir: Switching silenced genes back on with targeted demethylation
BIOCENTURY | EMERGING COMPANY PROFILEAPTADIR: SWITCHING SILENCED GENES BACK ON WITH TARGETED DEMETHYLATIONMilan-based biotech raised a €40M seed round to take RNA-DNA chimeras into the clinic,...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 weeks agoCSL, Voyager introduce incoming CEOs
BIOCENTURY | MANAGEMENT TRACKSCSL, VOYAGER INTRODUCE INCOMING CEOSAustralian biopharma taps ViiV’s Waterhouse; Swartz to succeed Sandrock at gene therapy company
Sun Pharma stops eye-care drug production at Indian plant amid quality issues
STAT+: Psilocybin’s lasting benefits prove elusive in mice
Tiziana touts multiple sclerosis win at lower dose as high dose misses mark
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
